Ron Bentsur, Chairman & CEO, 10% Owner at Nuvectis Pharma, Inc. (NVCT), bought 300 shares at $14.66 ($4K) on 2023-08-11, disclosed to the SEC on 2023-08-11.
Open-market purchase of $4k NVCT by Chairman & CEO, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.83 | 120 | $2K | 40.3% |
| 2 | $14.66 | 180 | $3K | 59.7% |
| Total | $14.73 avg | 300 | $4K | 100% |
| Filing → |
| NVCT | BUY | 2024-12-26 | $21K | — | Filing → |
| NVCT | BUY | 2024-11-18 | $98K | — | Filing → |
| NVCT | BUY | 2024-05-15 | $13K | — | Filing → |